<!DOCTYPE html>
<html lang="en">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Human Kratom Studies | FDA Clinical Trial and Pharmacokinetic Data</title>

<meta name="description" content="Structured review of FDA-registered human kratom studies, including clinical trial NCT06072170 and controlled pharmacokinetic evaluations of mitragynine and 7-hydroxymitragynine.">

<meta name="keywords" content="kratom human study, NCT06072170, mitragynine clinical trial, 7-hydroxymitragynine metabolism, kratom drug liking, FDA kratom study">

<meta name="author" content="Kratom Regulatory Review">
<meta name="theme-color" content="#0c2d48">

<link rel="canonical" href="https://kratomregulatoryreview.org/human-studies.html">

<!-- Open Graph -->
<meta property="og:title" content="Human Kratom Studies | FDA Clinical Trial Data">
<meta property="og:description" content="Regulatory review of controlled human kratom studies including pharmacokinetics, 7-OH formation, and drug-liking findings.">
<meta property="og:type" content="website">
<meta property="og:url" content="https://kratomregulatoryreview.org/human-studies.html">

<!-- Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-MQKC65VZVY"></script>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-P31PD1SSTD"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config','G-MQKC65VZVY');
gtag('config','G-P31PD1SSTD');
</script>

<link rel="stylesheet" href="../css/style.css">
  <style>

/* Page Layout */
.page-header {
  padding: 60px 0 30px 0;
}

.page-header h1 {
  font-size: clamp(28px, 4vw, 40px);
  font-weight: 700;
  margin-bottom: 14px;
}

.page-intro {
  max-width: 900px;
  margin-bottom: 18px;
  line-height: 1.75;
  font-size: 17px;
  color: #374151;
}

/* Section spacing */
.section {
  padding: 60px 0;
}

.section h2 {
  font-size: 24px;
  margin-bottom: 18px;
}

.alt-bg {
  background: #f8fafc;
}

/* Study Cards */
.card {
  border: 1px solid #e5e7eb;
  border-radius: 14px;
  padding: 28px;
  background: #ffffff;
  margin-bottom: 30px;
  box-shadow: 0 4px 12px rgba(0,0,0,0.03);
  transition: box-shadow 0.2s ease;
}

.card:hover {
  box-shadow: 0 6px 18px rgba(0,0,0,0.05);
}

.card h3 {
  font-size: 20px;
  margin: 0 0 14px 0;
  font-weight: 600;
  color: #0c2d48;
}

.card h4 {
  font-size: 15px;
  margin: 20px 0 8px 0;
  font-weight: 600;
  letter-spacing: 0.2px;
  color: #111827;
}

.card p {
  line-height: 1.7;
  margin-bottom: 12px;
  color: #374151;
}

.card ul {
  margin: 8px 0 14px 20px;
  padding-left: 0;
}

.card li {
  margin-bottom: 6px;
  line-height: 1.6;
}

/* Subtle divider inside cards */
.card hr {
  border: 0;
  border-top: 1px solid #e5e7eb;
  margin: 24px 0;
}

/* Notes */
.note {
  font-size: 14px;
  color: #6b7280;
  line-height: 1.6;
}

/* Links styled consistently */
.card a {
  font-weight: 600;
  text-decoration: underline;
  color: #0c2d48;
}

.card a:hover {
  opacity: 0.8;
}

/* Footer */
.footer {
  background: #0c2d48;
  color: #ffffff;
  padding: 40px 0;
  text-align: center;
  margin-top: 60px;
}

</style>

</head>
<body>

<div class="gov-banner">
üá∫üá∏ Informational public health resource. Educational reference for legislative and regulatory review.
</div>

<header class="site-header">
  <div class="container header-inner">
    <div class="site-title">Kratom Regulatory Review</div>
  </div>
</header>

<nav class="main-nav">
  <div class="container nav-inner">
    <a href="/index.html">Overview</a>
    <a href="/mortality.html">Mortality</a>
    <a href="/adverse.html">Adverse Events</a>
    <a href="/poison.html">Poison Control</a>
    <a href="/KratomCaseReports.html">Case Reports</a>
    <a href="/Human_studies/">Human Studies</a>
    <a href="/about.html">About</a>
  </div>
</nav>

<section class="page-header">
  <div class="container">
    <h1>Human Kratom Studies</h1>

    <p class="page-intro">
      This page summarizes controlled human studies evaluating kratom (Mitragyna speciosa)
      and its primary alkaloids, mitragynine and 7-hydroxymitragynine (7-OH).
    </p>

    <p class="page-intro">
      Included are one FDA-registered clinical research result and peer-reviewed pharmacokinetic
      investigations examining safety, metabolism, subjective effects, and dose response
      under controlled laboratory conditions.
    </p>

  </div>
</section>
 <section class="section">
  <div class="container">

   <!-- STUDY 1: HUESTIS 2026 SAFETY/TRIAL -->
<div class="card">
  <h3>Randomized Safety &amp; Tolerability Trial (Huestis et al., 2026)</h3>

  <p>
    This was a randomized, double-blind, placebo-controlled study evaluating
    single and repeated daily oral doses of dried kratom leaf powder
    (MitraLeaf) in healthy adult volunteers.
  </p>

  <h4>Study Design</h4>
  <ul>
    <li>116 participants total (49 active kratom; 67 placebo)</li>
    <li>Four escalating mitragynine dose levels: 6.65, 13.3, 26.6, and 53.2 mg</li>
    <li>Single dose phase followed by 15 consecutive daily doses</li>
    <li>23-day follow-up period</li>
    <li>Participants were healthy, nonsmoking adults who had not used kratom in ‚â•12 months</li>
  </ul>

  <h4>7-Hydroxymitragynine (7-OH) Formation</h4>
  <p>
    The MitraLeaf product contained &lt;0.01% 7-OH.
    The paper confirms that 7-OH detected in plasma primarily results
    from metabolic conversion of mitragynine (via CYP3A4),
    not from high 7-OH content in the plant material.
  </p>

  <h4>Adverse Events (TEAEs)</h4>
  <p>
    No serious adverse events or deaths were reported.
    Treatment-emergent adverse events (TEAEs) generally increased
    with higher dose levels.
  </p>

  <p><strong>Most common after single dose:</strong></p>
  <ul>
    <li>Nausea</li>
    <li>Dizziness</li>
    <li>Headache</li>
  </ul>

  <p><strong>Most common after 15 daily doses:</strong></p>
  <ul>
    <li>Headache</li>
    <li>Feeling hot</li>
    <li>Nausea</li>
    <li>Somnolence</li>
    <li>Increased ALT (alanine aminotransferase)</li>
  </ul>

  <p>
    Most TEAEs were mild in severity (approximately 90%+).
    A small number were moderate. Severe events were rare and resolved.
  </p>

  <h4>Drug Liking / Abuse-Related Signals</h4>
  <p>
    Abuse potential‚Äìrelated adverse events were monitored.
    Euphoric mood was reported in only three participants total
    (one in each active single-dose cohort and one in placebo).
  </p>

  <p>
    No participant reported euphoric mood during the multiple-dose phase
    after receiving active kratom.
  </p>

  <p>
    Only one withdrawal-related event (mild diarrhea) was reported
    during follow-up.
  </p>

  <h4>Early Terminations</h4>
  <p>
    Six participants were withdrawn early:
  </p>
  <ul>
    <li>Two due to elevated ALT (liver enzyme) increases</li>
    <li>One due to severe gastroenteritis</li>
    <li>One due to vasovagal syncope during blood draw</li>
    <li>One due to ALT increase not meeting Hy‚Äôs Law criteria</li>
    <li>One withdrew voluntarily after reporting multiple side effects</li>
  </ul>

  <p>
    ALT and AST elevations at the highest dose resolved after stopping dosing.
    No cases met FDA criteria for drug-induced liver injury (Hy‚Äôs Law).
  </p>

  <h4>Cardiovascular and Respiratory Findings</h4>
  <p>
    No clinically significant changes were observed in blood pressure,
    heart rate, respiratory rate, oxygen saturation, or ECG parameters.
    No QTc prolongation above regulatory concern thresholds was reported.
  </p>

  <h4>Sponsorship and Disclosure</h4>
  <p>
    The study was funded by NP Pharma.
    The clinical trial was conducted under institutional review board approval.
    Authors disclosed consultant relationships with the sponsor.
  </p>

  <p>
    <a href="Huestis%20study%202026.pdf" target="_blank">
      Open PDF: Huestis study 2026 ‚Üí
    </a>
  </p>
</div>


   <!-- STUDY 2: HUESTIS 2024 PK -->
<div class="card">
  <h3>Human Pharmacokinetics of Mitragynine and 7-OH (Huestis et al., 2024)</h3>

  <p>
    This study measured how mitragynine and 7-hydroxymitragynine (7-OH) appear in blood
    after a single dose and after repeated daily dosing (15 days) of oral, encapsulated dried kratom leaf powder.
  </p>

  <h4>Why this matters</h4>
  <p>
    The kratom powder contained very little pre-formed 7-OH (&lt;0.01%),
    yet measurable 7-OH was still detected in plasma after dosing.
    This indicates 7-OH exposure largely reflects metabolic conversion of mitragynine inside the body.
  </p>

  <h4>Key findings in plain language</h4>
  <ul>
    <li>Both mitragynine and 7-OH increased with higher doses.</li>
    <li>Steady-state concentrations were reached in about 8‚Äì9 days for mitragynine.</li>
    <li>7-OH steady state was reached in about 7 days at the higher dose levels (trough data were limited at the lowest doses).</li>
    <li>The 7-OH/mitragynine ratio was higher after single dosing and decreased somewhat after repeated dosing.</li>
  </ul>

  <h4>Half-life and accumulation</h4>
  <p>
    Mitragynine showed a long terminal half-life that increased with dose
    (reported up to ~43 hours after the highest single dose and ~61 hours after repeated dosing in one cohort).
    7-OH had a shorter half-life than mitragynine, but also increased with dose and showed variability at higher doses.
  </p>

  <p>
    With repeated daily dosing, mitragynine accumulation was described as low to moderate,
    while 7-OH showed minimal accumulation compared with mitragynine.
  </p>

  <h4>Sponsorship and conduct</h4>
  <p>
    The study reports it was funded by Johnson Foods, LLC (manufacturer of the MitraLeaf dried kratom leaf powder),
    and the clinical study was performed by SGS Nutrasource in Ontario, Canada.
    Authors disclosed consulting relationships with the sponsor.
  </p>

  <p>
    <a href="Huestis%20PK%202024.pdf" target="_blank">
      Open PDF: Huestis PK 2024 ‚Üí
    </a>
  </p>
</div>


   <!-- STUDY 3: FDA-REGISTERED TRIAL (CLINICALTRIALS.GOV) -->
<div class="card">
  <h3>FDA-Registered Human Study (ClinicalTrials.gov: NCT06072170)</h3>

  <p>
    This is an FDA-registered human study with results posted publicly on ClinicalTrials.gov.
    It evaluated kratom administered as a single dose under controlled conditions in adult participants.
    The results page provides standardized outcome reporting using structured measures commonly used
    in clinical research.
  </p>

  <h4>What the results page includes (plain language)</h4>
  <ul>
    <li>
      <strong>Study population and design:</strong>
      who was eligible, how dosing was performed, and the general study schedule.
    </li>
    <li>
      <strong>Measured alkaloid exposure:</strong>
      laboratory measurements after dosing, including mitragynine and the presence of
      7-hydroxymitragynine (7-OH) formed in the body through metabolism.
    </li>
    <li>
      <strong>Subjective effects:</strong>
      standardized questionnaires capturing participant-reported effects such as
      ‚Äúdrug liking,‚Äù ‚Äúfeeling high,‚Äù and overall drug effect.
    </li>
    <li>
      <strong>Adverse events:</strong>
      side effects recorded during the study period, including the number of participants
      who experienced each event and the severity classification used by the study team.
    </li>
    <li>
      <strong>Withdrawals and discontinuations:</strong>
      how many participants did not complete the study and the documented reason when reported.
    </li>
  </ul>

  <h4>Why this is relevant</h4>
  <p>
    ClinicalTrials.gov provides a standardized, public format for reporting clinical study outcomes.
    For regulatory and legislative review, these results are useful because they show:
    (1) what was measured, (2) how outcomes were defined, and (3) what effects were observed
    in a supervised setting at specific dose levels.
  </p>

  <p>
    This type of study helps characterize short-term dose response and reported subjective effects.
    It does not evaluate long-term daily use, dependence development, real-world retail product variability,
    or outcomes in vulnerable populations such as adolescents.
  </p>

  <p class="note">
    If you cite results from this trial, use the ClinicalTrials.gov ‚ÄúResults‚Äù tab as the primary source,
    since it includes structured outcome tables and standardized reporting fields.
  </p>

  <p>
    <a href="https://clinicaltrials.gov/study/NCT06072170?tab=results" target="_blank" class="btnlink">
      View Results on ClinicalTrials.gov ‚Üí
    </a>
  </p>
</div>

  </div>
</section>
</section>
  <section class="section alt-bg">
  <div class="container">

    <div class="card">
      <h3>Summary Across Controlled Human Studies</h3>

      <p>
        Controlled human studies of kratom remain limited in number, but the studies summarized here
        provide structured information on metabolism, short-term tolerability, and measurable subjective effects
        under supervised conditions.
      </p>

      <h4>Key Findings (Plain Language)</h4>
      <ul>
        <li>
          <strong>7-hydroxymitragynine (7-OH) is produced in the body.</strong>
          Even when the kratom product contains very little 7-OH, participants still develop measurable 7-OH in blood,
          indicating metabolic conversion from mitragynine.
        </li>
        <li>
          <strong>Higher doses increase exposure.</strong>
          Both mitragynine and 7-OH blood levels rise with dose, and repeated dosing results in sustained exposure.
        </li>
        <li>
          <strong>Drug-effect ratings increase at higher doses.</strong>
          In the FDA-registered single-dose study, higher doses were associated with statistically significant increases
          in subjective ratings such as ‚Äúdrug liking‚Äù and ‚Äúfeeling high.‚Äù
        </li>
        <li>
          <strong>Short-term side effects were common and dose-related.</strong>
          Nausea, dizziness, headache, sleepiness, and similar effects were reported more often at higher doses.
        </li>
        <li>
          <strong>Some participants were withdrawn.</strong>
          Withdrawals occurred for reasons including elevated liver enzymes at higher doses and gastrointestinal intolerance.
        </li>
      </ul>

      <hr>

      <h4>What These Studies Do Not Evaluate</h4>
      <ul>
        <li>Long-term, high-frequency chronic use over months or years</li>
        <li>Adolescents and pediatric exposures</li>
        <li>Population-level incidence (how common events are in the general public)</li>
        <li>Real-world retail variability, including concentrated extracts and polydrug use</li>
        <li>Development of dependence and withdrawal under long-term daily use</li>
      </ul>

      <p class="note">
        Controlled trials are designed to measure effects under specific conditions. Surveillance systems
        (mortality, poison control, adverse event reporting) capture broader real-world patterns and are presented
        elsewhere on this site.
      </p>
    </div>

    <div class="card">
      <h3>Primary References</h3>
      <ul>
        <li>
          FDA-registered study results (ClinicalTrials.gov): 
          <a href="https://clinicaltrials.gov/study/NCT06072170?tab=results" target="_blank">NCT06072170 ‚Üí</a>
        </li>
        <li>
          Therapeutic Drug Monitoring (2026) safety/tolerability trial (PDF):
          <a href="assets/Huestis%20study%202026.pdf" target="_blank">Open PDF ‚Üí</a>
        </li>
        <li>
          Molecules (2024) pharmacokinetics study (PDF):
          <a href="assets/Huestis%20PK%202024.pdf" target="_blank">Open PDF ‚Üí</a>
        </li>
      </ul>
    </div>

  </div>
</section>

<footer class="footer">
  <div class="container">
    <p>¬© 2026 Kratom Regulatory Review</p>
  </div>
</footer>

</body>
</html>
